ArticleJACC. Advances2026
Ivabradine Use and Exercise Capacity Post-Atrial Switch Repair for Transposition of Great Arteries.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are few proven therapies for improving exercise capacity in patients with transposition of the great arteries who have undergone an atrial switch repair.
objectivesThe objective of the study was to evaluate the effect of heart rate lowering using ivabradine on exercise capacity and quality of life in this cohort.
methodsIn this single-center, randomized, double-blind, crossover study, patients were randomized to ivabradine or placebo for 4 weeks then crossover treatment for 4 weeks. A cardiopulmonary stress test and quality of life assessment were performed at baseline then at weeks 4 and 8. Estimates of difference were described using a mixed effects model.
resultsA total of 19 patients were eligible and 10 patients completed the study. Compared to placebo, ivabradine treatment was associated with lower heart rate at baseline (65 ± 3 beats/min on ivabradine vs 79 ± 5 beats/min on placebo, difference -14.6 [-24, -5]; P = 0.008) and at peak exercise (131 ± 7 beats/min vs 146 ± 7 beats/min, difference -15.3 [-24, -6]; P = 0.003). Peak oxygen consumption was 20.4 ± 1.2 mL/kg/min on ivabradine vs 19.2 ± 1.2 mL/kg/min on placebo (difference +1.2 [-0.09, 2.6]; P = 0.06). Peak oxygen pulse was higher on ivabradine compared to placebo (12.5 ± 1.2 vs 10.7 ± 1.2 mL/beat, difference +1.7 [0.9, 2.6]; P = 0.002). Visual analog score was 73.5 ± 5.6 on ivabradine vs 62.5 ± 5.6 on placebo (mean difference 11.0 [-1.6, 23.6]; P = 0.08). One patient developed symptomatic bradycardia and one patient experienced phosphenes.
conclusionsIvabradine use in patients with transposition of the great arteries and atrial switch repair lowered peak heart rate with exercise and was associated with a higher oxygen pulse. (Effect of Ivabradine use on exercise capacity in patients with transposition of the great arteries [TGA] post atrial switch repair; ACTRN12621000196842).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.